WHO Collaborating Centres on Influenza definition

WHO Collaborating Centres on Influenza or “WHO CCs” means influenza laboratories designated by WHO and supported by national authorities to perform certain roles within the [WHO Network], and which have accepted formal Terms of Reference from WHO. In general, they differ from National Influenza Centres and WHO H5 Reference Laboratories in having global responsibilities and more extensive technical capacities. Consensus
Sample 1Sample 2
WHO Collaborating Centres on Influenza or “WHO CCs” means animal or human influenza laboratories designated by WHO and fully supported by national authorities to perform certain roles within the [WHO Network], and which have accepted formal Terms of Reference from WHO. In general, they differ from National Influenza Centres and WHO H5 Reference Laboratories in having global responsibilities and more extensive technical capacities. As of May 2008, WHO CCs included the WHO Collaborating Centres for Reference and Research on Influenza in London, Melbourne and Tokyo, the WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza in Atlanta and the WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals in Memphis.
Sample 1Sample 2

Examples of WHO Collaborating Centres on Influenza in a sentence

  • WHO Collaborating Centres on Influenza and WHO H5 Reference Laboratories and the Director-General will actively continue to provide technical assistance to Member States to enhance research and surveillance capacity, including staff training, with the objective of improving national pandemic risk assessment and pandemic risk response.

  • WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and Essential Regulatory Laboratories, working with the WHO Secretariat, will continue to make available to National Influenza Centres and Other authorized laboratories, without charge, supplies of noncommercial diagnostic reagents and test kits for the identification and characterization of clinical specimens of influenza.

  • Member States may also provide PIP biological materials directly to any other party or body on a bilateral basis provided that the same materials are provided on a priority basis to the WHO Collaborating Centres on Influenza and/or H5 Reference Laboratories under this Framework.

  • By providing PIP biological materials from National Influenza Centres and Other authorized laboratories to WHO Collaborating Centres on Influenza and WHO H5 Reference Laboratories as set out in paragraph 5.1.1(i) above, Member States provide their [prior informed consent] / [consent] for the onward transfer and use of PIP biological materials to the institutions, organizations and entities [as set out in 5.1.1(ii)].

  • However: 4.1.1 National Influenza Centres and Other authorized laboratories in developing and least developed countries may charge a nominal administrative fee to recover the costs of shipping, handling, storage or other direct administrative overheads associated with transferring the PIP biological materials to WHO Collaborating Centres on Influenza and/or H5 Reference Laboratories.

  • The Terms of Reference of the WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories, National Influenza Centres and Essential Regulatory Laboratories should be developed in accordance with the guiding principles outlined in Attachment 3 to this Framework.

  • Other researchers solely for influenza related research other than developing and/or producing vaccines, diagnostics and pharmaceutical products and Other biological products.] (iii) Essential Regulatory Laboratories, on receiving PIP biological materials from WHO Collaborating Centres on Influenza or WHO H5 Reference Laboratories may transfer PIP biological materials only to respective WHO Collaborating Centres on Influenza and NICs of the originating country.

  • Provision of diagnostic reagents and test kits (Section 6.4) 6.4.1 WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and Essential Regulatory Laboratories, working with the WHO Secretariat, will continue to make available to National Influenza Centres and Other authorized laboratories, without charge, supplies of noncommercial diagnostic reagents and test kits for the identification and characterization of clinical specimens of influenza.

  • The Terms of Reference of the WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories, National Influenza Centres [and Essential Regulatory Laboratories] are at Annex 31 to this Framework.

  • Other researchers solely for influenza related research other than developing and/or producing vaccines, diagnostics and pharmaceutical products and Other biological products.] (iii) Essential Regulatory Laboratories, on receiving PIP biological materials from WHO Collaborating Centres on Influenza or WHO H5 Reference Laboratories may transfer PIP biological materials only to respective to WHO Collaborating Centres on Influenza and NICs of the originating country.

Related to WHO Collaborating Centres on Influenza

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Collaboration Technology means all Collaboration Patents and Collaboration Know-How.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Collaboration has the meaning set forth in Section 2.1.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Collaborative lawyer means a lawyer who represents a party in a collaborative law process.

  • Collaborating physician means the physician who,

  • Licensor Technology means the Licensor Patents, the Licensor Know-How, Licensor Materials, Product IP, and Licensor’s rights in the Program IP and Joint Patents.

  • Third Party Technology means all Intellectual Property and products owned by third parties and licensed pursuant to Third Party Licenses.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaborative matter means a dispute, transaction, claim, problem, or issue for resolution, including a dispute, claim, or issue in a proceeding, that is described in a collaborative law participation agreement and arises under the family or domestic relations law of this state, including any of the following:

  • Research Use shall have the meaning given in Section 2.2.2 of this Agreement.

  • Collaboration Term has the meaning set forth in Section 2.2.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Research Program has the meaning set forth in Section 2.1.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Autism spectrum disorders means any of the pervasive developmental disorders as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, published by the American Psychiatric Association, including autistic disorder, Asperger's disorder and pervasive developmental disorder not otherwise specified.[PL 2011, c. 420, Pt. A, §26 (RAL).]

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Program Technology means Program Know-How and Program Patents.

  • Phase IV Clinical Trial means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by BMS and that otherwise fit the foregoing definition.